Media headlines about Ekso Bionics (NASDAQ:EKSO) have trended somewhat negative this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ekso Bionics earned a daily sentiment score of -0.01 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.801012827295 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Global Bionic Exoskeletons Market 2017 – Recent Study Including Growth Factors, Applications, Regional Analysis, Key Players and Forecasts till 2022 (newsient.com)
- Medical Bionics Market is Forecasted to Generate a Revenue of $28.1 Billion By 2023: P&S Market Research (globenewswire.com)
- Head-To-Head Contrast: Ekso Bionics (EKSO) vs. Altra Industrial Motion (AIMC) (americanbankingnews.com)
- Ekso Bionics (EKSO) versus Nordson (NDSN) Head-To-Head Review (americanbankingnews.com)
- Is there a market for this wearable robot for skiers? (zdnet.com)
Separately, Zacks Investment Research raised shares of Ekso Bionics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th.
Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Tuesday, March 13th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.05). Ekso Bionics had a negative net margin of 396.04% and a negative return on equity of 246.15%. The firm had revenue of $2.45 million during the quarter. research analysts predict that Ekso Bionics will post -0.35 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3341689/ekso-bionics-ekso-getting-somewhat-critical-press-coverage-analysis-shows.html.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.